Skip to main content
. 2018 Sep 17;9(10):934. doi: 10.1038/s41419-018-0989-8

Table 1.

Patient related information and IC50 values in the primary cells

ID Age Stage and histology Treatment status Source for primary culture IHC IHC IC50 (µM)
Post op 6 cycles chemo (C + P) Progression at 6 months Ascites Chemo naive PAX8 WT1
PCAST-1 65 IIIC HGCS no 34.7 ± 0.02
PCAST-3 45 IVC HGSC yes 19.6 ± 0.5
PCAST-4 52 IIIC HGSC no 28.5 ± 0.08
PCAST-6 52 IIIB (Clear cell) no 23.2 ± 0.02
PCAST-12 40 IIIC (HGSC) no 23.2 ± 0.01
PCAST-14 46 IIIC (HGSC) x yes 22.3 ± 0.02
PCAST-15 56 IIIC (HGSC) no 30 ± 0.5
PCAST-16 56 IVB (HGSC) no 27.4 ± 0.15
PCAST-17 64 IIIC (HGSC) x no 14.5 ± 0.15

Clinical data of patient sample/primary cells includes patient age, stage/histology treatment status and origin. We confirmed the epithelial ovarian cancer cells (EOC) by IHC of various markers (PAX8, WT1). PCAST- primary culture ascites; HGSC- high-grade serous cancer; C + P- carboplatin + paclitaxel.

PCAST primary culture ascites, HGSC high-grade serous cancer, C+P carboplatin + paclitaxel